Sign in
Taking people in South KoreaPhase 3

Screening people with Alzheimer's disease for possible future studies

Checks whether adults with Alzheimer's disease may qualify for later research studies.

Key facts

Who runs it
Hoffmann-La Roche
Where
Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, and Suwon, South KoreaSee the 13 sitesAlso in 14 other countries, 221 sites
Trial code
Registry title
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Status
Recruiting
Phase
Phase 3
People taking part
80,000 people, planned
Started
2 Jul 2025
Expected to end
31 Jul 2035
Type of study
Interventional
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

This is a pre-screening study. It checks whether people could join one of Roche's Alzheimer's disease trials, using biomarker tests and thinking tests.

Age
50 Years to 90 Years
Sex
All sexes can join.
Disease stage
Alzheimer's disease. People with a clinical diagnosis of MCI or mild AD are named in the record.
Biomarker or test result
Biomarker status is checked. People with MCI or mild AD who already have a biomarker-confirmed AD diagnosis (amyloid PET, cerebrospinal fluid or blood biomarker) cannot join.

Main reasons for not taking part

  • Needs help with basic daily activities because of memory or thinking problems
  • Sight or hearing problems that stop the thinking tests (glasses and hearing aids are allowed)
  • Another brain or nerve condition that may cause memory or thinking problems
  • Severe head or brain injury with clinical significance in the past
  • Serious medical condition that makes taking part in a study unsafe

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
  • Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study

Who cannot take part

  • For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary
  • Dependency in basic activities of daily living (bADLs) due to cognitive impairment
  • Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
  • Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
  • History of severe, clinically significant central nervous system trauma
  • Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 90 years old?

Where in South Korea

Also in 14 other countries, 221 sites

  • Chonnam National University HospitalGwangju, South KoreaTaking people
  • St. Vincent's HospitalGyeonggi-do, South KoreaNo longer taking part
  • Inha University HospitalIncheon, South KoreaTaking people
  • Gachon University Gil Medical CenterNamdong-gu, South KoreaTaking people
  • Seoul National University Bundang HospitalSeongnam-si, South KoreaTaking people
  • Asan Medical CenterSeoul, South KoreaTaking people
  • Ewha Womans University Hospital (Seoul)Seoul, South KoreaTaking people
  • Gangnam Severance HospitalSeoul, South KoreaTaking people
  • Hanyang University Seoul HospitalSeoul, South KoreaTaking people
  • Konkuk University Medical CenterSeoul, South KoreaTaking people
  • Korea University Guro HospitalSeoul, South KoreaTaking people
  • Samsung Medical CenterSeoul, South KoreaTaking people
  • Ajou University Medical CenterSuwon, South KoreaTaking people

About the trial

What the trial wants to find out

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

The group in the trial

  • Screening ArmOther group

    Participants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
Plain-language title
Screening people with Alzheimer's disease for possible future studiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07177352, who can take part
Record updated
19 October 2026